Across TCGA pan-cancer cohorts, TMEM184B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM184B data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM184B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM184B expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where TMEM184B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.948	0.618	<.001	65	view →
LSCC	DFS	Median	All	0.595	0.832	.019	11	view →
PDAC	DFS	Quartile	All	0.230	0.807	.039	4	view →
GBM	DFS	Quartile	All	0.851	0.430	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TMEM184B tumor-vs-normal RNA expression · all TMEM184B data types